Key result
Emerging evidence suggests the mechanisms of hemostasis and thrombosis can be separated, highlighting new antithrombotic targets like the Mac-1 and GPIbα interaction to reduce bleeding risk.
Targeting the interaction between leukocyte integrin αMβ2 and platelet GPIbα may provide a novel antithrombotic strategy that reduces bleeding risk by sparing hemostasis.
Hypothesis-generating for safer antithrombotics sparing hemostasis; leaves open clinical translation pending prospective trials.
Current antithrombotic drugs, including widely used antiplatelet agents and anticoagulants, are associated with significant bleeding risk. Emerging experimental evidence suggests that the molecular and cellular mechanisms of hemostasis and thrombosis can be separated, thereby increasing the possibility of new antithrombotic therapeutic targets with reduced bleeding risk. We review new coagulation and platelet targets and highlight the interaction between integrin αMβ2 (Mac-1, CD11b/CD18) on leukocytes and GPIbα on platelets that seems to distinguish thrombosis from hemostasis.
No takes yet. Share an insight, caveat, or question.
Plow et al. (2018) conducted a review in Thrombosis. New antithrombotic mechanisms and therapies was evaluated. Emerging evidence suggests the mechanisms of hemostasis and thrombosis can be separated, highlighting new antithrombotic targets like the Mac-1 and GPIbα interaction to reduce bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: